Luis G. Paz-Ares, MD, PHD Special Presentation June 1st, 2019 McCormick Place Hall D2, 3pm
Luis G. Paz-Ares, MD, PHD will be presenting Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial June 1st, 2019 McCormick Place Hall D...
Author: PharmaMar
Added: 05/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - May 28, 2019 Category: Cancer & Oncology Source Type: podcasts
GRACEcast 420 WCLC 2015 Practices Changed Prophylactic Cranial Irradiation Extensive Stage SCLC [360p]
Drs. Ben Solomon, Leora Horn, & Jack West discuss whether the data highlighting cognitive deficits from whole brain radiation therapy (WBRT) for patients with brain metastases should change our recomm...
Author: cancergrace
Added: 03/30/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 30, 2019 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy for Lung Cancer [360p]
Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.
Author: cancergrace
Added: 03/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Second Line Chemotherapy Options for SCLC [360p]
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Author: cancergrace
Added: 03/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2019 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy for Small Cell Lung Cancer [360p]
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center reviews early trial data of immunotherapy agents for treatment of small cell lung cancer (SCLC).
Author: cancergrace
Added: 03/14/2019 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2019 Category: Cancer & Oncology Source Type: podcasts
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.
Author: BeaconMedIC
Added: 12/20/2018 (Source: Oncology Tube)
Source: Oncology Tube - December 20, 2018 Category: Cancer & Oncology Source Type: podcasts
IMpower133: Is there Finally a New Standard of Care for Extensive Stage SCLC? (BMIC-064)
Dr. Jack West reviews the IMpower133 trial that integrated atezolizumab with first line chemo for extensive stage SCLC and discusses whether the results improve outcomes enough to change our standard ...
Author: BeaconMedIC
Added: 11/05/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Emerging New Agents In SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 1, 2018 Category: Cancer & Oncology Source Type: podcasts
Upcoming SCLC Data
Pascal Besman Chief Operating Officer at PharmaMar discusses Upcoming SCLC Data. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Progress In SCLC Vs. NSCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Progress In SCLC Vs. NSCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
IO Likely In 1st Line SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses IO Likely In 1st Line SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.<br />
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Emerging New Agents In SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Emerging New Agents In SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Current Standard Of Care In SCLC
Pascal Besman Chief Operating Officer at PharmaMar discusses Current Standard Of Care In SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018.
Author: Cancer-News
Added: 10/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 30, 2018 Category: Cancer & Oncology Source Type: podcasts
Differences Between NSCLC & SCLC
Pascal Besman Chief Operating Officer at PharmaMar Discusses Differences Between NSCLC & SCLC. At ESMO Oncology Conference - Munich, Germany On October 19, 2018
Author: kidneycancer
Added: 10/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 26, 2018 Category: Cancer & Oncology Source Type: podcasts
TRINITY: Rova-T for relapsed SCLC
Treatment options for small cell lung cancer (SCLC) have not advanced significantly in the past few decades, and patients with multiple relapses have no approved treatment options. In this video, reco...
Author: VJOncology
Added: 07/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 27, 2018 Category: Cancer & Oncology Source Type: podcasts
